-
6 days ago | 
nature.com | Alex Bataller |Hannah Goulart |Ghayas C. Issa |Courtney DiNardo |Tapan M Kadia |Ian Bouligny | +12 more
AbstractAcute myeloid leukemia (AML) with KMT2A rearrangement (KMT2Ar) has poor outcomes. We analyzed 1,611 patients with AML and 4.3% demonstrated rearrangements in KMT2A. Signaling-related genes (NRAS 30%, KRAS 23% and FLT3-TKD 16%) were the most frequently mutated in patients with KMT2Ar AML.
-
1 month ago | 
nature.com | Jayastu Senapati |Guillermo Garcia-Manero |Courtney DiNardo |Gautam Borthakur |Tapan M Kadia |Elias Jabbour | +8 more
Despite the improvement in overall outcomes of patients with acute myeloid leukemia (AML), some high-risk disease subsets continue to fare dismally. AML with TP53 aberrations (mutations, deletions) is one such subset of high-risk AML with a median survival of about 6–9 months [1,2,3].
-
1 month ago | 
nature.com | Mahesh Swaminathan |Courtney DiNardo |Naveen Pemmaraju |Guillermo Garcia-Manero |Ghayas C. Issa |Gautam Borthakur | +9 more
To the Editor:The advent of VEN (VEN) has changed the treatment paradigm of acute myeloid leukemia (AML). Currently, venetoclax (VEN), in combination with a hypomethylating agent (HMA), is approved for the treatment of adult patients with AML unsuitable for intensive chemotherapy or frontline treatment of patients ≥75 years [1].
-
1 month ago | 
nature.com | Alex Bataller |Koji Sasaki |Danielle Hammond |Mahesh Swaminathan |Ghayas C. Issa |Nicholas Short | +6 more
AbstractHypomethylating agents (HMA) are indicated in the treatment of higher-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). The combination of hypomethylating agents with venetoclax (Ven) has demonstrated promising results in these diseases, although randomized clinical trials are needed for validation.
-
Jan 8, 2025 | 
onclive.com | Hagop Kantarjian
Phase I/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R/R AMLDr. Hagop Kantarjian presents the Phase I/II SAVE trial results, showcasing the promising efficacy and safety of the all-oral combination of revumenib, decitabine/cedazuridine, and venetoclax in relapsed/refractory AML, achieving high response rates and MRD negativity in heavily pretreated patients.
-
Jan 6, 2025 | 
onlinelibrary.wiley.com | Hagop Kantarjian |Nicholas Short |NITIN JAIN |Fadi Haddad |Tapan Mahendra Kadia |Musa Yilmaz | +8 more
Conflicts of Interest H.K. received research grants from AbbVie, Amgen, Ascentage, BMS, Daiichi-Sankyo, Immunogen, Jazz, Novartis, Pfizer; and honoraria from AbbVie, Amgen, Aptitude Health, Ascentage, Astellas Health, Astra Zeneca, Ipsen, Pharmaceuticals, KAHR Medical Ltd., NOVA Research, Novartis, Pfizer, Precision Biosciences, and Taiho Pharmaceutical Canada.
-
Aug 23, 2024 | 
nature.com | Branko Cuglievan |Hagop Kantarjian |Courtney DiNardo |Tapan M Kadia |Erin Guest |Nicholas Short | +18 more
AbstractAberrant expression of HOX and MEIS1 family genes, as seen in KMT2A-rearranged, NUP98-rearranged, or NPM1-mutated leukemias leads to arrested differentiation and leukemia development. HOX family genes are essential gatekeepers of physiologic hematopoiesis, and their expression is regulated by the interaction between KMT2A and menin.
-
Aug 3, 2024 | 
onlinelibrary.wiley.com | Elias Jabbour |Hagop Kantarjian
1 DISEASE OVERVIEW Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm with an annual incidence of two cases/100 000. It accounts for approximately 15% of newly diagnosed adult leukemia cases.1 In 2024, an estimated 9280 new CML cases will be diagnosed in the United States (US), and about 1280 patients will die of CML (due to its high prevalence today).
-
Dec 15, 2023 | 00552-9/abstract&sz=64)
mayoclinicproceedings.org | Hagop Kantarjian |Amir T. Fathi |Vincent Rajkumar
Perspectives and controversies | Innovation in Medicine and SurgeryVolume 99, Issue 1p15-21 aDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston bSection of Hematology, Department of Internal Medicine, Yale University School of Medicine and Yale Comprehensive Cancer, New Haven, CT cLeukemia Program, Massachusetts General Hospital, Boston dDepartment of Leukemia, Memorial Sloan Kettering Cancer Center, New York, NY eDepartment of Internal Medicine, Mayo Clinic,...
-
Nov 30, 2023 | 
nature.com | Hagop Kantarjian |Koji Sasaki
The early mortality rate after a medical procedure or treatment has been a historical measure of quality of care delivery. It was originally developed to assess the risk of surgeries or other procedures and later adopted across medical practices to evaluate differential risks of early mortality with similar therapies to define favorable or unfavorable outliers, and to improve delivery of care.
